Here are the 10-Q quarterly reports from Filana Therapeutics, Inc. (FLNA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FLNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLNA filings page.
Filana Therapeutics, Inc. reported a third-quarter 2026 net loss of $10.7 million, compared with $10.8 million a year earlier. Nine-month net loss was $29.7 million versus $78.4 million, while research and development expense was $11.7 million versus $22.7 million, reflecting completion of the Alzheimer’s program phase-out in the second quarter of 2025.
The FDA lifted the full clinical hold on simufilam’s planned Phase 2a study in TSC-related epilepsy on September 22, 2026. The planned trial is 16 weeks, randomized and double-blind, targeting 40 participants at 13 U.S. sites; screening is expected to begin by the first quarter of 2027.
Cash and cash equivalents were $47.0 million at September 30, 2026; $31.25 million was restricted in escrow for a settlement subject to court approval and unavailable for general operations. Nine-month operating cash use was $18.8 million, compared with $22.5 million. During the quarter, the at-the-market program sold 1,760,000 shares at a weighted-average $1.16, generating approximately $2.0 million gross and $1.6 million net; approximately $48 million remained available. Nasdaq’s initial compliance period for the $1.00 minimum bid-price requirement runs through March 16, 2027.
Filana Therapeutics, Inc., a clinical‑stage CNS biotech, reported a net loss of $8.6 million for Q2 2026 and $18.9 million for the six months ended June 30, 2026, lower than the prior‑year periods as research and development and general and administrative expenses declined.
Cash and cash equivalents were $82.7 million at June 30, 2026, with total assets of $103.9 million and stockholders’ equity of $63.6 million; management believes current working capital will meet needs for at least the next 12 months. The company has no product revenue and an accumulated deficit of $515.0 million.
Development is centered on lead candidate simufilam for TSC‑related epilepsy, but the related IND is on full clinical hold pending additional data and protocol changes. Legal matters remain significant, including a previously paid $40 million SEC civil penalty and a proposed $31.25 million securities class‑action settlement that has been accrued and funded into escrow, contributing to $32.75 million of litigation reserves.
Filana Therapeutics, Inc. reported a Q1 2026 net loss of $10.3 million, improving from $23.4 million a year earlier, as research and development spending fell to $4.5 million from $13.7 million after discontinuing its Alzheimer’s program. Cash and cash equivalents were $86.6 million and total stockholders’ equity was $68.1 million as of March 31, 2026. The company carries an accumulated deficit of $506.4 million and has reserved $32.75 million for litigation-related contingencies, including $31.25 million tied to a proposed securities class action settlement. Management believes existing working capital will fund operations for at least the next 12 months while it focuses on developing simufilam for TSC‑related epilepsy under an FDA clinical hold.